- within Food, Drugs, Healthcare and Life Sciences topic(s)
- with readers working within the Chemicals and Healthcare industries
What happens when an FDA advisory committee recommends opening the door to peptide compounding, but FDA staff strongly disagree? In this episode, we unpack the FDA Pharmacy Compounding Advisory Committee’s recommendation to add six of seven peptides under review to the 503A Bulks List for uses ranging from obesity and wound healing to insomnia, despite agency staff raising concerns about insufficient safety and effectiveness data, limited clinical evidence, and potential safety risks. We also explore why the recommendations are not a green light for compounding or marketing these substances: FDA must still complete a formal rulemaking process, and the agency is not required to follow the Committee’s advice. For compounding pharmacies, wellness providers, telehealth platforms, manufacturers, and investors, the key takeaway is clear: enforcement risk remains, and caution is still warranted.
Hosted by Simone Roach. Based on a blog post by Donnelly L. McDowell and Cristina Ferretti.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]
